Sleep Medicine
Volume 5, Issue 5 , Pages 435-440 , September 2004

Epidemiology of restless legs syndrome as diagnosed in UK primary care

  • David A.M.C. van de Vijver

      Affiliations

    • Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute of Pharmaceutical Sciences (UIPS), P.O. Box 80 082, 3508 TB Utrecht, The Netherlands
    • Present address: Department of Virology, University Medical Centre Utrecht, Utrecht, The Netherlands.
    • Corresponding Author InformationCorresponding author. Tel: +31-30-253-7324; fax: +31-30-253-9166.
    • ,
  • Thomas Walley

      Affiliations

    • Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK
    • ,
  • Hans Petri

      Affiliations

    • Worldwide Epidemiology, GlaxoSmithKline, Harlow, UK

Received 20 April 2004 ,Revised 1 July 2004 ,Accepted 2 July 2004.

References 

  1. Allen RP, Earley CJ. Restless legs syndrome: a review of clinical and pathophysiologic features. J Clin Neurophysiol. 2001;18:128–147
  2. Earley CJ. Clinical practice. Restless legs syndrome. N Engl J Med. 2003;348:2103–2109
  3. Lee KA, Zaffke ME, Baratte-Beebe K. Restless legs syndrome and sleep disturbance during pregnancy: the role of folate and iron. J Womens Health Gend Based Med. 2001;10:335–341
  4. Winkelmann J, Stautner A, Samtleben W, Trenkwalder C. Long-term course of restless legs syndrome in dialysis patients after kidney transplantation. Mov Disord. 2002;17:1072–1076
  5. O'Keeffe ST, Gavin K, Lavan JN. Iron status and restless legs syndrome in the elderly. Age Ageing. 1994;23:200–203
  6. Walters AS. Toward a better definition of the restless legs syndrome. The International Restless Legs Syndrome Study Group. Mov Disord. 1995;10:634–642
  7. Allen R, Picchietti D, Hening W, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003;4:101–119
  8. Ulfberg J, Nystrom B, Carter N, Edling C. Prevalence of restless legs syndrome among men aged 18 to 64 years: an association with somatic disease and neuropsychiatric symptoms. Mov Disord. 2001;16:1159–1163
  9. Rothdach AJ, Trenkwalder C, Haberstock J, et al. Prevalence and risk factors of RLS in an elderly population. The MEMO study. Neurology. 2000;54:1064–1068
  10. Henning W, Walters AS, Allen RP, et al. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med. 2004;5:237–246
  11. Garcia Rodriguez LA, Perez-Gutthann S, Jick S. The UK General Practice Research Database. In:  Strom BL editors. Pharmacoepidemiology. Chichester: Wiley; 2000;p. 375–386
  12. Chaudhuri KR, Appiah-Kubi LS, Trenkwalder C. Restless legs syndrome. J Neurol Neurosurg Psychiatry. 2001;71:143–146
  13. Ohayon MM, Roth T. Prevalence of restless legs syndrome and periodic limb movement disorder in the general population. J Psychosom Res. 2002;53:547–554
  14. Walters AS, Hickey K, Maltzman J, et al. A questionnaire study of 138 patients with restless legs syndrome: the Night-Walkers survey. Neurology. 1996;46:92–95
  15. Montplaisir J, Boucher S, Poirier G, et al. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord. 1997;12:61–65
  16. Hening WA, Walters AS, Chokroverty S. Motor functions and dysfunctions of sleep. In:  Chokroverty S editors. Sleep disorders medicine. Boston: Butterworth-Heinemann; 1994;p. 255–293
  17. Dehlin O, Bengtsson C, Rubin B. A comparison of zopiclone and propiomazine as hypnotics in outpatients: a multicentre, double-blind, randomized, parallel-group comparison of zopiclone and propiomazine in insomniacs. Curr Med Res Opin. 1997;13:565–572
  18. Wetter TC, Brunner J, Bronisch T. Restless legs syndrome probably induced by risperidone treatment. Pharmacopsychiatry. 2002;35:109–111
  19. British Medical Association and the Royal Pharmaceutical Society of Great Britain . British National Formulary. Wallingford, Oxon: Pharmaceutical; 1998;
  20. Walker G, for the Association of British Pharmaceutical Industry . ABPI data sheet compendium 1990–1991. London: Datapharm; 1991;
  21. Saletu M, Anderer P, Hogl B, et al. Acute double-blind, placebo-controlled sleep laboratory and clinical follow-up studies with a combination treatment of rr-l-dopa and sr-l-dopa in restless legs syndrome. J Neural Transm. 2003;110:611–626
  22. Stiasny K, Wetter TC, Winkelmann J, et al. Long-term effects of pergolide in the treatment of restless legs syndrome. Neurology. 2001;56:1399–1402
  23. Saletu M, Anderer P, Saletu B, et al. Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 2. Findings on periodic leg movements, arousals and respiratory variables. Neuropsychobiology. 2000;41:190–199
  24. Montplaisir J, Denesle R, Petit D. Pramipexole in the treatment of restless legs syndrome: a follow-up study. Eur J Neurol. 2000;7(suppl. 1):27–31

PII: S1389-9457(04)00123-6

doi: 10.1016/j.sleep.2004.07.003

Sleep Medicine
Volume 5, Issue 5 , Pages 435-440 , September 2004

Article Tools

* Image Usage & Resolution